AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.

Lukas BunseAnne-Kathleen RuppIsabel PoschkeTheresa BunseKatharina LindnerAntje WickJens BlobnerMartin MischGhazaleh TabatabaiMartin GlasOliver SchnellJens GemptMonika DenkGuido ReifenbergerMartin BendszusPatrick WuchterJoachim P SteinbachWolfgang WickMichael Platten

Published in: Neurological research and practice (2022)

NCT03893903.

Keyphrases

wild type
double blind
phase iii
open label
phase ii
high grade
study protocol
clinical trial
placebo controlled
low grade
cancer therapy
cross sectional
randomized controlled trial